Research programme: cancer therapeutics - EiRx
Latest Information Update: 19 Feb 2007
At a glance
- Originator EiRx Therapeutics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Feb 2007 Changed profile name from anticancer therapeutics to cancer therapeutics
- 29 Jan 2004 Preclinical trials in Cancer in Ireland (unspecified route)